Ocular Toxicity of Iron Chelator Drugs among Thalassemia Patients; a Review by Nassiri, Nader & Hashemieh, Mozhgan
Journal of Ophthalmic and Optometric Sciences. Volume 1, Number 5, Autumn 2017. 31
This work is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Review Article
Ocular Toxicity of Iron Chelator Drugs among 
Thalassemia Patients; a Review
Nader Nassiri 1, MD; Mozhgan Hashemieh *2, MD  
1. Department of Ophthalmology, Imam Hossein Medical Center, Shahid Beheshti University of 
Medical Sciences, Tehran, Iran. 
2. Department of Pediatric Hematology Oncology, Imam Hossein Medical Center, Shahid 
Beheshti University of Medical Sciences, Tehran, Iran. 
*Corresponding Author: Mozhgan Hashemieh 
E-mail: mozh_hash@yahoo.com
Article Notes:
Received: Jun. 6, 2017
Received in revised form:
Aug. 6, 2017
Accepted: Aug. 22, 2017









Transfusion dependent thalassemia is a hematological condition 
characterized by imbalance in synthesis of alpha and beta 
subunits of hemoglobin. The consequence of regular and repeated 
transfusions is iron deposition in different organs. In order to 
survive, these patients need iron chelator drugs. The oldest drug of 
this group is desferrioxamine which is administered subcutaneously 
or intravenously. Nowadays, oral iron chelator drugs, including 
deferiprone and deferasirox are in more widespread use since they 
are more convenient. In this review the ocular toxicity of these 
chelator drugs is discussed.
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Introduction 
Thalassemia syndromes are a type of hereditary 
hemolytic anemia characterized by reduction 
or absence of b-chains synthesis1. Iran is 
located on thalassemia belt with an overage 
carrier rate of 4 % 2,3. It is estimated that each 
year 60,000 to 70,000 beta thalassemia cases 
are born most of them in the Mediterranean 
area, Middle East, Far East and East Asia 4. The 
main part of management for these patients is 
regular transfusions. The consequence of these 
repeated transfusions is iron accumulation in 
vital organs, such as heart, liver, endocrine 
glands and kidneys 5. Therefore to improve 
the survival of thalassemia patients, iron 
chelator drugs are used 6. Without adequate 
transfusion and chelation, the life expectancy 
among thalassemia patients is much lower 
than normal population 7. 
Thalassemia can affect eyes 8. Ocular 
complications of thalassemia syndromes 
can be due to different factors such as 
chronic hypoxia, bone marrow expansion, 
iron overload and deferoxamine toxicity 9. 
Three iron chelators have been approved for 
iron chelation in thalassemia: deferoxamine 
(DFO), deferiprone (DFP) and deferasirox 
(DFX) 10. DFO was the first generation of 
iron chelators administered intravenously 
or subcutaneously over duration of 8-10 
hours per day; 5-7 days week 11. The 
most common side effects of DFO are 
local irritation, redness and itching at the 
site of injection, skeletal changes, ocular 
abnormalities and auditory disturbances 
such as hearing lass and tinnitus 12. The life-
threatening side effect of oral chelator drug 
DFP is agranulocytosis, which can be fatal 
13. DFX is another oral iron chelator which 
is usually used once-daily. Gastrointestinal 
disturbances, fever, headache, cough, mild 
to moderate elevation of the creatinine level, 
elevation of liver enzymes, hearing loss and 
ocular disturbances including cataracts and 
retinal disorders have been reported as the 
side effects of this drug 14. In this review the 
ocular toxicity of these chelator drugs will 
be discussed.
Ocular side effects of deferoxamine
Ocular findings in beta thalassemia may be 
caused by the disease itself, iron overload or 
chelator drugs 9. Baath et al., have reported 
an incidence of 1.2 % for opthalmologic 
complications of DFO, but their low sample 
size of just 84 patients receiving regular DFO 
treatment for transfusional hemochromatosis 
related to long-term hypertransfusion makes 
this percentage somehow unreliable 15. In 
other studies this incidence has been reported 
to be between 1 % to 9 %12. 
There seems to be no clear relationship 
between drug dosage and development of 
DFO retinopathy, but intravenous DFO 
presents a greater risk of retinal toxicity 
compared to subcutaneous and intramuscular 
forms of DFO 15. Other probable risk factors 
include blood-retinal barrier breakdown 
among diabetic patients, rheumatoid arthritis, 
renal failure and metabolic encephalopathy 12.
The mechanism of DFO ocular toxicity is not 
well understood but the ocular side effects 
of DFO were first suggested to be caused by 
chelation of metals, which are essential for 
normal retinal function, in particular copper, 
by DFO 16.  A direct effect not secondary to 
trace element depletion, caused by cell death 
due to activation of p38 mitogen activated 
protein kinases, has also been suggested 12.
The probable ocular side effects of DFO 
include decreased visual acuity or acute 
visual loss, color vision abnormalities, 
impaired visual field, night blindness, angioid 
streaks, retrobulbar optic neuritis, bull’s eye 
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maculopathy, vitelliform maculopathy and 
macular or peripheral pigmentary degeneration 
9,12,16-19. 
There is no gold standard for identification 
of the ocular toxicity caused by DFO prior 
to its development 12. Patients might show 
changes in their response to visual evoked 
potentials testing after DFO administration20. 
However in majority of cases, investigations 
such as electroretinography and fluorescein 
angiography are carried out only when an 
abnormality is found in clinical history or 
physical examination of the eye 15. Currently, 
there are no approved guidelines for the follow-
up and no agreed upon treatment for DFO 
ocular toxicity other than drug discontinuation 
or dose reduction 12. A maximum dose of 
50 mg/kg of body weight and tapering the dose 
as the hepatic iron concentration approaches 
normal levels is suggested to minimize the 
ocular toxicity 12. 
Ocular side effects of deferiprone and 
deferasirox
Nowadays because of inconvenient use of 
DFO, the majority of thalassemia patients 
consume oral iron chelator agents like DFP, 
which also have fewer systemic side effects 21. 
DFP provides effective retinal iron chelation 
because of its ability to cross the blood-retinal 
barrier without retinal toxicity 18,22. Posterior 
subcapsular opacity and retinal pigment 
epithelium degeneration due to deferiprone 
use have been reported 18,23-27. Deferasirox 
is another oral iron chelator with no retinal 
penetration 28. Lens opacities, reversible 
retinopathy, and toxic maculopathy have been 
reported in patients using this drug 29-33. It 
should be noted that since DFP and DFX are 
comparatively new drugs compared to DFO, 
our body of knowledge about their ocular 
toxicity is very limited, consisting of mostly 
anecdotal case reports. 
Discussion
Eye practitioners need to consider ocular 
complications caused by thalassemia itself, 
transfusional iron overload, or iron chelators 
when examining a thalassemia patient and 
close follow-up using various imaging 
modalities may help to lessen ocular damage 
among these patients 18. It should be noted that 
chelator drugs are the cause of some ocular 
complications among thalassemic patients, 
but most of the ocular complications in beta-
thalassemia patients are caused by the disease 
itself 9.
Regular ophthalmic screening should be 
carried out for thalassemic patients receiving 
chelator drugs because early detection of eye 
toxicity caused by these drugs may lead to 
optimization of the drug dosage and prevent 
the long-term visual consequences 15. It has 
been suggested that ophthalmic screening 
should be performed at three months intervals 
along with maintaining therapeutic  levels of 
desferrioxamine under 0.025 microgram/l of 
blood to help in prevention and reversal of 
ocular toxicity among thalassemic patients 34.
Taher et al. have reported that the type of 
iron chelating agent used had no influence 
on the decrease in visual acuity 23. There are 
conflicting reports about the reversibility 
of chelator drugs ocular toxicity. Retinal 
changes and visual deficits might recover after 
cessation of the medication, but some authors 
have reported permanent visual deterioration 
or progression of ocular complications, 
even after drug discontinuation 15,35. Rahi 
et al., 36 reported a case who presented with 
both central scotoma and constriction of the 
peripheral field in each eye, which resolved 
after withdrawal of high-dose therapy. Also 
Marciani et al., 37 in their study of high-dose 
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DFO therapy in patients with iron overload 
reported reversible visual impairment without 
significant changes in brain electrical activity. 
In contrast Bene et al., 38 have reported a case 
of irreversible visual loss after deferoxamine 
usage. Similarly Simon et al., 34 have reported 
a 29-year-old patient receiving repeated blood 
transfusions for β thalassemia since childhood 
developing blindness and peripheral visual 
field loss shortly after commencing high-dose 
intravenous desferrioxamine. In their case the 
recovery was partial following cessation of 
desferrioxamine 34. 
In brief although the ocular toxicity of iron 
chelator drugs among thalassemia patients 
is relatively rare it might cause devastating 
consequences for the patient. The proper 
management of these patients includes regular 
eye exams, early detection of toxicity and 
discontinuation of the causative drug, which 
needs close coordination between the eye 
specialists and hematologists managing these 
patients.
Conclusion
Iron chelator drugs might cause various ocular 
side effects. Regular ophthalmic screening in all 
thalassemia patients receiving iron chelator drugs 
is recommended to avoid delayed diagnosis and 
irreversible damage to patients’ eyes.  
Nassiri et al.Ocular Toxicity of Iron Chelator Drugs
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